Selection of Candidate Compounds Sample Clauses

The 'Selection of Candidate Compounds' clause defines the process by which specific chemical or biological compounds are chosen for further research, development, or commercialization within a collaborative project or agreement. Typically, this clause outlines the criteria, procedures, and decision-making responsibilities for identifying which compounds will advance to subsequent stages, such as preclinical or clinical evaluation. By establishing a clear framework for selection, the clause helps ensure that both parties agree on the compounds of interest, thereby reducing disputes and streamlining project progression.
Selection of Candidate Compounds. Either Party or the Parties together, through the Exploratory Team, may propose Compounds to the Joint Steering Committee to be selected as Candidate Compounds. The proposal shall include a summary business case, a proposed plan for Screening Activities (including the time, costs and resources anticipated for such activities and associated budget) and the PoC Criteria to be tested during the Screening Activities, in a format to be agreed to in writing by the Parties (the “Screening Plan”). It is expected that TOTAL will have a major role identifying potential Candidate Compounds and neither Party shall unreasonably delay its approval or disapproval of any potential Candidate Compound proposed by the other Party.
View SourceView Similar (3)
Selection of Candidate Compounds. For a period of [***] after designation of a Recommended Compound, Sankyo shall have the right to conduct further preclinical development and evaluation of such Recommended Compound under the Research Program, and to determine in its sole discretion whether such Recommended Compound is appropriate to conduct more extensive preclinical development under this Agreement to evaluate its potential as a clinical candidate. If, within such [***] period, Sankyo gives written notice to MTI that the appropriate research and development committee of Sankyo has selected such Recommended Compound to conduct further preclinical development under this Agreement, thereafter such Recommended Compound shall be a Candidate Compound.
View SourceView Similar (2)
Selection of Candidate Compounds. For a period of [CONFIDENTIAL -------------------------------- TREATMENT REQUESTED] after designation of a Recommended Compound, Sankyo shall have the right to conduct further preclinical development and evaluation of such Recommended Compound under the Research Program, and to determine in its sole discretion whether such Recommended Compound is appropriate to conduct more extensive preclinical development under this Agreement to evaluate its potential as a clinical candidate. If, within such [CONFIDENTIAL TREATMENT REQUESTED] period, Sankyo gives written notice to Gensia Sicor that the appropriate research and development committee of Sankyo has selected such Recommended Compound to conduct further preclinical development under this Agreement, thereafter such Recommended Compound shall be a Candidate Compound.
View Source

Related to Selection of Candidate Compounds

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.